
    
      The intravenous device will be randomly attributed. The adjuvant chemotherapy regimen will be
      selected according the standards of the center ( 6 cycles of FEC100 or 3 cycles of FEC100
      then 3 cycles of Taxotere (docetaxel). The patient will be followed as per center's standards
      and visits (prior, during and after every drug administration, then monthly for six months).
      All Adverse Events will be reported.
    
  